

PRODUCT INFORMATION

SARS-CoV-2 Spike Protein S1-Receptor-Binding Domain-Kappa (B.1.617.1)_HEK

Description:

InVivo offers a recombinant form of the Spike protein receptor binding domain (RBD) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), based on Wuhan-Hu-1-isolate (MN908947), which is produced under serum-free conditions in HEK-INV cells (InVivo proprietary optimized; human embryonic kidney, HEK293 cells).

RBD-Kappa (B.1.617.1) variant; containing mutations L452R, E484Q.

Protein design and manufacturing process is based on InVivo's RBD protein (aa 319-541). The protein includes a C-terminal hexa-histidine-tag and is purified using immobilized metal exchange chromatography (IMAC) and preparative SEC (for polishing).

Product-ID:	S1-RBD-Kappa (B.1.617.1)_HEK
Expression System:	Mammalian; HEK
Protein Accession Number:	GenBank: QHD43416.1 / UniProt: P0DTC2
Amino Acids:	Arg319-Phe541, modified as mentioned above
Mutations:	L452R, E484Q
Mature Protein N-Term:	Arg319 (predicted)
Tag:	6 x His-Tag; C-terminal
Expected Molecular Weight:	26 kDa (<i>glycosylated form runs at 25-40 kDa in gel electrophoresis</i>)
Formulation:	Liquid, 20 mM NaPP, 300 mM NaCl pH 7.2
Concentration:	≥ 0.5 mg/ mL
Purity:	≥ 90% (<i>via analytical CGE under reducing conditions</i>)

The product is for research use or for further manufacturing only.